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background:  In most patients requiring lipid-lowering therapy, statins are the treatment of choice due to their ability to reduce 
cardiovascular (CV) events. However, treatment options in patients who are statin intolerant and those who do not yet meet the thresholds 
for statin initiation (e.g., young dyslipidemics with low short-term CV risk but high or very high life-time CV risk) remains uncertain. In such 
patients, hypolipidemic nutritional supplements may offer a potential therapeutic option but their safety and lipid-lowering efficacy have 
heretofore not been systematically evaluated in randomized clinical studies.
Methods:  We tested the efficacy and safety of PreLipid®, a nutritional supplement containing standardized extracts of red yeast rice, 
grape seed and coenzyme Q10, in this investigator initiated, randomized, double blind, placebo controlled study conducted at 9 sites in 
India. 210 newly diagnosed hyperlipidemic [low-density lipoprotein-cholesterol (LDL-C) >120 mg/dL] patients (mean age 46.6 ± 10.2 yrs, 
56.6% males) with no history of CV disease were randomized to receive one capsule of either PreLipid® or placebo twice daily (along 
with life style modification) for 12 weeks. Adverse events and effects on lipid and safety parameters [liver enzymes, serum creatinine and 
glycosylated hemoglobin] were monitored.
Results:  Mean baseline LDL-C was 148.5 ± 24.0 mg/dL and 148.6 ± 21.9 mg/dL in the PreLipid® and placebo group respectively. 
Compared to placebo, PreLipid® resulted in significant (p<.0001), time-dependent reduction in LDL-C (-23.44% vs -5.59% at week 4, 
-28.98 % vs 0.78% at week 12) and total cholesterol (-18.31% vs -3.83% at week 4, -23.30% vs -2.13% at week 12) with no difference in 
any safety parameter. No treatment related adverse event was observed in the PreLipid® group.
conclusion:  This study demonstrates the efficacy and safety of PreLipid® in LDL-C and total cholesterol lowering after 12 weeks of 
treatment. Nearly 30% reduction in LDL-C at week 12 with PreLipid® is comparable to reductions seen with moderate-intensity statin 
therapy. Long-term studies are needed to determine the impact of PreLipid® on clinical outcomes.(NCT02187757; www.essens-study.com)
